Table 2.
Depression treatment pattern among adults with MS and depression (NAMCS-NHAMCS 2005–2011).
| Unweighted freq | Wt. freq (millions) | Wt.% | |
|---|---|---|---|
| Overall depression treatment | 133 | 1.205 | 57.25 |
| Overall psychotherapy use | 18 | 0.094 | 4.48 |
| Overall antidepressant use | 126 | 1.169 | 55.54 |
|
| |||
| Antidepressant class and individual antidepressant use | |||
|
| |||
| SNRI | 32 | 0.417 | 35.04 |
| Desvenlafaxine | 2 | 0.117 | 10.04 |
| Duloxetine | 13 | 0.208 | 17.76 |
| Venlafaxine | 18 | 0.092 | 7.85 |
| SSRI | 78 | 0.651 | 55.67 |
| Citalopram | 9 | 0.062 | 5.32 |
| Escitalopram | 19 | 0.154 | 13.16 |
| Fluoxetine | 20 | 0.234 | 20.05 |
| Paroxetine | 5 | 0.096 | 8.18 |
| Sertraline | 25 | 0.105 | 8.99 |
| TCAs | 11 | 0.07 | 3.32 |
| Amitriptyline | 4 | 0.015 | 1.25 |
| Desipramine | 1 | 0.003 | 0.29 |
| Doxepin | 2 | 0.043 | 3.63 |
| Nortriptyline | 4 | 0.009 | 0.80 |
| Serotonin Modulators | 12 | 0.107 | 5.08 |
| Trazodone | 12 | 0.107 | 5.08 |
| Miscellaneous | 15 | 0.147 | 6.97 |
| Bupropion | 11 | 0.069 | 3.25 |
| Mirtazapine | 4 | 0.078 | 3.72 |
Note. Based on 220 (nationally representative weighted N = 2.104 million) ambulatory visits of adults (age ≥ 18 years) with Multiple Sclerosis and depression using NAMCS and NHAMCS 2005–2011 data.
MS: Multiple Sclerosis; Wt.: weighted; freq: frequency; NAMCS: National Ambulatory Medical Care Survey; NHAMCS: National Hospital Ambulatory Medical Care Survey.
Did not observe use of the following antidepressants: Amoxapine, Clomipramine, Imipramine, Maprotiline, Protriptyline, Trimipramine, Vilazodone, Vortioxetine, and Nefazodone.